Elevated Soluble ACE2 Activity in Children and Adults After SARS‐CoV‐2 Exposure Irrespective of Laboratory‐Confirmed Infection
Authors:
- Maximilian StichMSMaximilian Stich
- Vladimir Gonçalves MagalhãesVMVladimir Gonçalves Magalhães
- Sven F. GarbadeSGSven F. Garbade
- Kathrin JeltschKJKathrin Jeltsch
- Anneke HaddadAHAnneke Haddad
- Roland EllingRERoland Elling
- Peter LangPeter Lang
- Armin RabsteynARArmin Rabsteyn
- Eva‐Maria JacobsenEJEva‐Maria Jacobsen
- Sebastian F. N. BodeSBSebastian F. N. Bode
Open Access
- 3 December 2024
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (12) , e70098
Abstract
The pivotal role of the cell entry receptor ACE2 for SARS‐CoV‐2 infection is well‐established. When ACE2 is shed from cell surface into plasma as soluble ACE2 (sACE2), it can effectively neutralize SARS‐CoV‐2. This longitudinal prospective cohort study analyzed sACE2 activity in 1192 participants, aged 4 months to 81 years, 3 and 12 months after SARS‐CoV‐2 household exposure. Following SARS‐CoV‐2 exposure, participants exhibited significantly elevated sACE2 activity, irrespective of confirmed infection, with the highest levels observed in exposed children. Longitudinal analysis revealed a decline in sACE2 levels over time, reaching levels comparable to age‐ and sex‐matched pre‐pandemic controls. An increase in sACE2 activity was also confirmed in vitro in Calu‐3 (human lung) cells within hours of SARS‐CoV‐2 exposure, providing a direct link between SARS‐CoV‐2 exposure and elevated sACE2. This study, therefore, challenges the dichotomy of categorizing SARS‐CoV‐2 exposed participants as infected or not infected solely on currently established diagnostic assays. It demonstrates lasting host responses independent of B‐ and T‐cell memory and may help to keep SARS‐CoV‐2 infections in balance and contribute to successful virus clearance in children and adults lacking humoral and cellular immune responses following SARS‐CoV‐2 exposure.Trial Registration: German Registry for Clinical Studies; Identifier: D 00021521.Keywords
This publication has 50 references indexed in Scilit:
- Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different genderMedicine, 2018
- Circulating ACE2 in Cardiovascular and Kidney DiseasesCurrent Medicinal Chemistry, 2017
- The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical ResearchCurrent Drug Targets, 2017
- Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transportersPharmacology & Therapeutics, 2010
- Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63Journal of Virology, 2010
- Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entryProceedings of the National Academy of Sciences, 2008
- Tumor Necrosis Factor-α Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2)Journal of Biological Chemistry, 2005
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005
- The Pulmonary Renin-Angiotensin SystemCurrent Pharmaceutical Design, 2003
- Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzymeFEBS Letters, 2002